Eligible patients, consecutively recruited, had HF with left ventricular ejection fraction <40% and were placed on sodium–glucose co-transporter-2 inhibitors (SGLT2-i) within 3 months of recruitment. The gene discussed is SLC5A2; the disease is hydrops fetalis.